Navigation Links
Co-Sponsorship of Pulmonary Fibrosis Research Enhancement Act Increases to 27 Members
Date:11/11/2008

SAN JOSE, Calif., Nov. 11 /PRNewswire-USNewswire/ -- The CPF today announced that the Pulmonary Fibrosis Research Enhancement Act (PFREA) (H.R. 6567) - which would authorize $16 million in new federal funding for pulmonary fibrosis (PF) research - has now gained the support of 27 Members of the U.S. House of Representatives.

PFREA is first of its kind legislation to improve research and awareness of pulmonary fibrosis, a terminal lung disease with no known cause, no FDA approved treatment and no cure. (For more information on PF, visit http://www.coalitionforpf.org). The PFREA is expected to be re-introduced in the 111th Congress in early 2009. However, additional Members of Congress could be added on as co-sponsors in the current Congress if there is a lame duck Congressional session.

"We are pleased to see the Pulmonary Fibrosis Research Enhancement Act gaining momentum. This bill is critical to finding treatments and saving lives from this devastating disease," said Mishka Michon, Chief Executive Officer of the CPF. "We are thankful for the leadership Brian Baird and Mike Castle have given to this effort."

The PFREA was originally introduced in Congress on July 22, 2008 by Representative Brian Baird (D-WA) and Representative Mike Castle (R-DE). Congressman Baird lost his father to pulmonary fibrosis, and Congressman Castle lost his brother and sister to the devastating disease. A substantial portion of the $16 million authorization would be used to establish a comprehensive national registry of PF patients. The Act would also:

-- Mandate the creation of a National PF Action Plan, in conjunction with

the National Institutes of Health (NIH) and the Centers for Disease

Control (CDC), which would focus on strategies to improve public

awareness of PF, and accelerate patient and medical education

strategies. The Action Plan would be provided to the Director of the

NIH within one year of the Act's passage.

-- Establish a National PF Advisory Board, which would make recommendations

to the NIH and CDC concerning the structure and management of a PF

patient registry. The goal of the registry would be to improve

understanding of the cause(s) and progression of PF, improve standards

of care, accelerate research, and develop new therapies sooner.

-- Establish a National Summit on PF, to foster collaboration between

Federal Agencies, researchers, patients and advocates to identify new

approaches to research and treat PF. The Summit would be held every

three years.

To view the legislation in its entirety, please visit http://thomas.loc.gov/ and type in "Pulmonary Fibrosis Research Enhancement Act" in the search box for bills.

To date, the following Members of Congress have agreed to co-sponsor H.R. 6567:

-- Thomas Allen - Maine

-- Rob Bishop - Utah

-- Earl Blumenauer - Oregon

-- Dennis Cardoza - California

-- Mike Castle - Delaware

-- Nathan Deal - Georgia

-- Diana DeGette - Colorado

-- Jim Gerlach - Pennsylvania

-- Virgil Goode - Virginia

-- Bob Goodlatte - Virginia

-- Bart Gordan - Tennessee

-- Jane Harman- California

-- Marcy Kaptur - Ohio

-- Mark Kirk - Illinois

-- Tom Latham - Louisiana

-- Steven LaTourette - Ohio

-- Zoe Lofgen - California

-- Jim Marshall - Georgia

-- Bill Pascrell - New Jersey

-- David Price - North Carolina

-- Jackie Speier - California

-- John Tierney - Massachusetts

-- Henry Waxman - California

-- Peter Welch - Vermont

-- Robert Wexler - Florida

-- Frank Wolf - Virginia

-- C.W. "Bill" Young - Florida

The CPF is actively advocating for the Bill's passage, and is asking its 17,000 members, and all those who are affected by PF, to voice their support for HR 6567 by visiting http://www.coalitionforpf.org/cpf_advocacy.php and becoming a CPF advocate. By joining the ACT campaign, you will become part of an army of volunteers who are contacting Congress, national health policymakers and the media to educate them about the PF. Every three months, members will receive free the CPF's ACT Action Alert, a newsletter detailing the advocacy efforts and outlining ways you can help. The CPF's advocacy program allows you to easily contact your Member of Congress immediately to voice your support. For further information, please visit the CPF at http://www.coalitionforpf.org, call us at 888-222-8541, or email us at info@coalitionforpf.org.

About Pulmonary Fibrosis (PF)

IPF is a lung disorder characterized by a progressive scarring - known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from IPF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. IPF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis.

About the Coalition for Pulmonary Fibrosis

The Coalition for Pulmonary Fibrosis (CPF) is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for idiopathic pulmonary fibrosis (IPF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure pulmonary fibrosis; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of IPF issues; and works to improve awareness of IPF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 17,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with pulmonary fibrosis. For more information please visit http://www.coalitionforpf.org or call (888) 222-8541.


'/>"/>
SOURCE Coalition for Pulmonary Fibrosis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Viagra Bulk Effectively Cures Children with PAH (Pulmonary Arterial Hypertension)
2. Women at Higher Risk for Pulmonary Hypertension
3. Cialis May Help Ease Pulmonary Hypertension
4. Tomophase to Exhibit First In-vivo Cross-sectional Images of Pulmonary Stenting Using Proprietary OCT System
5. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
6. The U.S. Surgeon General Issues National Call-to-Action on Deep-Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
7. LSUHSC study finds high-dose HBO2 therapy extends survival window after cardiopulmonary arrest
8. American Lung Association Commends U.S. House of Representatives for Passage of Pulmonary and Cardiac Rehabilitation Act
9. Simple Case Management Cuts Pulmonary Disease Admissions
10. A guided broncoscope achieves biopsy of 75 percent pulmonary nodules without puncture or surgery
11. COPD patients benefit more from pulmonary rehab in earlier stages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... NY & Salt Lake City, UT (PRWEB) , ... February 05, ... ... Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author ... the New Really Cool Humans Amateur TV Network. , Each week, on his weekly ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to once again host, Swirl, A Wine Tasting Event at the La Gorce ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: